Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...

A fourth of patients with TRK fusion primary central nervous system tumors responded to the TRK inhibitor larotrectinib ...

Glioblastoma typically kills within 18 months, but a new type of treatment has kept Nadya El-Afandi's scans clear 17 months ...

Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a ...

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the ...

Memorial Sloan Kettering Cancer Center-led researchers have identified a small molecule called gliocidin that kills ...

A team led by researchers at the University of Toronto has uncovered new targets that could be the key to effectively ...

The global glioblastoma multiforme treatment market size was valued at USD 2.78 billion in 2024 and is expected to reach around USD 5.68 billion by 2033, registering a CAGR of 8.23% from 2024 to 2033.

As the first cohort of patients are dosed as part of the first stage of the Phase II trial, the company has announced the ...